Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Early Diagnosis and Successful Treatment of Idiopathic Autoimmune Factor XIII Deficiency Complicated by Intracerebral Hemorrhage

Mihoko Takai, MD, Naoko Hosono, MD., PhD., Shinji Kishi, MD, PhD, Takahiro Yamauchi, MD, PhD, Yoshimasa Urasaki, MD, PhD, Hiroyuki Neishi, MD, Hiroaki Takeuchi, MD, PhD, Masaharu Souri, PhD, Ken-ichiro Kikuta, MD, PhD, Toshihiro Haba, MD., PhD., Akitada Ichinose, MD, PhD, Takanori Ueda, MD, PhD

Blood (2012) 120 (21): 4634.

https://doi.org/10.1182/blood.V120.21.4634.4634

Published: 2012

Journal Articles

Marked Upregulations of Survivin and Aurora-B Kinase Are Associated with Disease Progression in the Myelodysplastic Syndromes,

Akira Yoshida, MD, PhD, Kouichi Zokumasu, Takahiro Yamauchi, MD, PhD, Kazutaka Takagi, MD, PhD, Shinji Kishi, MD, PhD, Yoshimasa Urasaki, MD, PhD, Kaoru Tohyama, MD, PhD, Takanori Ueda, MD, PhD

Blood (2011) 118 (21): 3823.

https://doi.org/10.1182/blood.V118.21.3823.3823

Published: 2011

Journal Articles

Whole-Body Diffusion-Weighted Magnetic Resonance Imaging Is a New Sensitive Non-Invasive Method for Staging and Monitoring Chemotherapy Response of Malignant Lymphoma Including Indolent Lymphoma Compared with FDG-PET/CT

Shinji Kishi, MD, PhD, Tatsuro Tsuchida, MD, PhD, Takahiro Yamauchi, MD, PhD, Naoko Hosono, MD, PhD, Satoshi Ikegaya, MD, PhD, Yoshimasa Urasaki, MD, PhD, Hidehiko Okazawa, MD, PhD, Hirohiko Kimura, MD, PhD, Takanori Ueda, MD, PhD

Blood (2010) 116 (21): 4147.

https://doi.org/10.1182/blood.V116.21.4147.4147

Published: 2010

Journal Articles

Prominent Elevation of Survivin Expression in High-Risk Myelodysplastic Syndrome.

Akira Yoshida, MD, PhD, Saki Tanaka, Takahiro Yamauchi, Kazutaka Takagi, Shinji Kishi, MD, PhD, Yoshimasa Urasaki, MD, PhD, Kaoru Tohyama, Takanori Ueda, MD, PhD

Blood (2009) 114 (22): 4842.

https://doi.org/10.1182/blood.V114.22.4842.4842

Published: 2009

Journal Articles

Unique Pharmacokinetic Self-Potentiation of Idarubicin through Induction of Carbonyl Reducing Enzymes in Contrast to Other Anthracyclines, Pharmacologic and Clinical Study

Shinji Kishi, MD, PhD, Taro Yamashita, MD, PhD, Toshihiro Fukushima, MD, PhD, Yoshimasa Urasaki, MD, PhD, Tamami Seo, MD, PhD, Toru Nakamura, MD, PhD, Toshihiro Haba, MD, PhD, Ken-ichi Kamiya, MD, PhD, Jun Murakami, MD, PhD, Mikio Ueda, MD, PhD, Shinji Nakao, MD, PhD, Takanori Ueda, MD, PhD

Blood (2008) 112 (11): 4025.

https://doi.org/10.1182/blood.V112.11.4025.4025

Published: 2008

Journal Articles

Unique Resistance Mechanism to Dexamethasone by Glutathione S-Transferase M1 Involving p38 MAPK and NF-κB Pathways, Possible Prognostic Role for Childhood ALL.

Naoko Hosono, MD, Shinji Kishi, MD., PhD., Sumiko Iho, PhD., Yoshimasa Urasaki, MD., PhD., Akira Yoshida, MD., PhD., Hisanori Kurooka, PhD., Yoshifumi Yokota, MD., PhD., Takanori Ueda, MD., PhD.

Blood (2007) 110 (11): 2375.

https://doi.org/10.1182/blood.V110.11.2375.2375

Published: 2007

Journal Articles

Anti-Tumor Effect of INNO-406, a Novel Bcr-Abl Inhibitor in Combination with Cyclosporin A Against the Murine Central Nervous System and Systemic Leukemia Model.

Asumi Yokota, Shinya Kimura, Satohiro Masuda, Eishi Ashihara, Yoshimasa Urasaki, Yasuhito Terui, Martin Ruthardt, Takanori Ueda, Kiyohiko Hatake, Ken-ichi Inui, Taira Maekawa

Blood (2007) 110 (11): 1598.

https://doi.org/10.1182/blood.V110.11.1598.1598

Published: 2007

Journal Articles

Cyclosporin A, a P-gp Inhibitor, Augments the Anti-Central Nervous System Ph + Leukemia Effects of INNO-406.

Asumi Yokota, Shinya Kimura, Satohiro Masuda, Eishi Ashihara, Yoshimasa Urasaki, Yasuhito Terui, Martin Ruthardt, Takanori Ueda, Kiyohiko Hatake, Ken-ichi Inui, Taira Maekawa

Blood (2006) 108 (11): 834.

https://doi.org/10.1182/blood.V108.11.834.834

Published: 2006

Journal Articles

INNO-406, a novel BCR-ABL/Lyn dual tyrosine kinase inhibitor, suppresses the growth of Ph + leukemia cells in the central nervous system, and cyclosporine A augments its in vivo activity

Asumi Yokota, Shinya Kimura, Satohiro Masuda, Eishi Ashihara, Junya Kuroda, Kiyoshi Sato, Yuri Kamitsuji, Eri Kawata, Yasuyuki Deguchi, Yoshimasa Urasaki, Yasuhito Terui, Martin Ruthardt, Takanori Ueda, Kiyohiko Hatake, Ken-ichi Inui, Taira Maekawa

Blood (2006) 109 (1): 306–314.

https://doi.org/10.1182/blood-2006-03-013250

Published: 2006

Includes: Supplemental data

Journal Articles

Anti-Tumor Activity of a Novel Bcr-Abl/Lyn Dual Inhibitor, NS-187, in Murine CNS Ph + Leukemia Models.

Asumi Yokota, Shinya Kimura, MD, Tatsuya Oyama, Eishi Ashihara, MD, Haruna Naito, PhD, Yoshimasa Urasaki, MD, Takanori Ueda, MD, Yasuhito Terui, MD, Kiyohiko Hatake, MD, Kazuko Hirabayashi, PhD, Taira Maekawa, MD

Blood (2005) 106 (11): 493.

https://doi.org/10.1182/blood.V106.11.493.493

Published: 2005

Journal Articles

The third-generation bisphosphonate zoledronate synergistically augments the anti-Ph + leukemia activity of imatinib mesylate

Junya Kuroda, Shinya Kimura, Hidekazu Segawa, Yutaka Kobayashi, Toshikazu Yoshikawa, Yoshimasa Urasaki, Takanori Ueda, Fumio Enjo, Harukuni Tokuda, Oliver G. Ottmann, Taira Maekawa

Blood (2003) 102 (6): 2229–2235.

https://doi.org/10.1182/blood-2003-01-0305

Published: 2003

NARROW

Early Diagnosis and Successful Treatment of Idiopathic Autoimmune Factor XIII Deficiency Complicated by Intracerebral Hemorrhage

Marked Upregulations of Survivin and Aurora-B Kinase Are Associated with Disease Progression in the Myelodysplastic Syndromes,

Whole-Body Diffusion-Weighted Magnetic Resonance Imaging Is a New Sensitive Non-Invasive Method for Staging and Monitoring Chemotherapy Response of Malignant Lymphoma Including Indolent Lymphoma Compared with FDG-PET/CT

Prominent Elevation of Survivin Expression in High-Risk Myelodysplastic Syndrome.

Unique Pharmacokinetic Self-Potentiation of Idarubicin through Induction of Carbonyl Reducing Enzymes in Contrast to Other Anthracyclines, Pharmacologic and Clinical Study

Unique Resistance Mechanism to Dexamethasone by Glutathione S-Transferase M1 Involving p38 MAPK and NF-κB Pathways, Possible Prognostic Role for Childhood ALL.

Anti-Tumor Effect of INNO-406, a Novel Bcr-Abl Inhibitor in Combination with Cyclosporin A Against the Murine Central Nervous System and Systemic Leukemia Model.

Cyclosporin A, a P-gp Inhibitor, Augments the Anti-Central Nervous System Ph + Leukemia Effects of INNO-406.

INNO-406, a novel BCR-ABL/Lyn dual tyrosine kinase inhibitor, suppresses the growth of Ph + leukemia cells in the central nervous system, and cyclosporine A augments its in vivo activity

Anti-Tumor Activity of a Novel Bcr-Abl/Lyn Dual Inhibitor, NS-187, in Murine CNS Ph + Leukemia Models.

The third-generation bisphosphonate zoledronate synergistically augments the anti-Ph + leukemia activity of imatinib mesylate

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only